ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria
- PMID: 36220763
- DOI: 10.1016/j.jcf.2022.09.011
ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria
Abstract
This paper is the first in a series providing updated guidance on the definition, evaluation and management of people with a Cystic Fibrosis Transmembrane conductance Regulator (CFTR)-Related Disorder (CFTR-RD). The need for this update relates to more precise characterisation of CFTR gene variants and improved assessment of CFTR protein dysfunction. The exercise is co-ordinated by the European CF Society Standards of Care Committee and Diagnostic Network Working Group and involves stakeholder engagement. This first paper was produced by a core group using an extensive literature review and papers graded for their quality. Subsequent wider stakeholder agreement was achieved. The definition of a CFTR-RD remains "a clinical condition with evidence of CFTR protein dysfunction that does not fulfil the diagnostic criteria for CF". Clearer guidance on CFTR dysfunction and relevant CFTR variants will be provided. Thresholds for clinical presentations are presented and the paradigm that pathobiological processes may be evident in more than one organ is agreed. In this paper we reflect on the early patient journey, highlighting that CF specialists as well as other relevant specialists should be involved in the care of people with a CFTR-RD.
Keywords: CFTR; CFTR biomarkers; CFTR related disorders; CFTR sequence variations; Cystic fibrosis; Follow-up; Intestinal current measurement; Nasal potential difference; Sweat test; Treatment.
Copyright © 2022. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest Carlo Castellani reports payments of honoraria for presentations from Vertex Pharmaceuticals and Chiesi and participation to Advisory Boards of Vertex Pharmaceuticals. Mylan, Actelion and Chiesi. Kris De Boeck reports consulting fees from Vertex Pharmaceuticals, Arcturus, Splisense, Translate Bio and Chiesi and honoraria for lectures from Vertex Pharmaceuticals. Elke De Wachter reports that her Institution received fundings from Vertex for her participation in an Advisory Board and for a presentation. Isabelle Sermet-Gaudelus reports funding for academic research from Vertex Therapeutics and participation to Scientific Boards of Vertex Therapeutics and Eliox; support for attending conferences by Vertex Therapeutics. Nicholas Simmonds reports payment of honoraria for lectures from Vertex, Chiesi, Gilead and Teva; participation to Advisory Boards of Vertex, Chiesi, Gilead and Menarini. Kevin Southern reports no competing interests
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
